Accountability for reasonableness
Open accessAbstract
All health systems struggle with the issue of meeting population health needs fairly under resource constraints. Decisions about the implementation of new technologies provide a useful window into the larger issue, and a paper in this week's journal provides a valuable insight into the elements of decision making that decision makers themselves think important in trying to reach fair decisions on applying new technologies in health care.1 In mixed systems, like that in the United States, decisions whether to fund new technologies—drugs, devices, procedures—are made both by public agencies, such as the Health Care Financing Administration or the Veterans Administration, and by private indemnity insurers and managed care organisations. In the universal coverage systems of most developed countries such decisions are made by public agencies or authorities. Distrust has grown in all these settings.2,3 Clinicians, patients, and the public—propelled by the media, the internet, and direct to consumer advertising—often believe these decisions are guided solely by the “bottom line,” not patient welfare. The moral legitimacy of limits and priorities thus involves not just who has moral authority to set them, but how they are set. Some countries with universal coverage systems initially tried to address this problem of legitimacy by setting up national commissions to articulate principles that should govern the setting of priorities. Holm has argued that these principles proved too general and too unclear in practice.4 More generally, we probably lack consensus on principles capable of resolving disputes about rationing.5 A second wave of efforts to address priority setting has thus focused on developing fair, publicly acceptable processes for making these decisions. In the United States an active consumer movement has also focused on a patients' bill of rights as a vehicle for fair process. In the United Kingdom, awareness of the need for clear process is reflected in the establishment of the National Institute for Clinical Excellence (NICE) to handle some aspects of rationing.6,7 In pluralist societies we are likely to find reasonable disagreement about principles that should govern priority setting. For example, some will want to give more priority to the worst off, some less; some will be willing to aggregate benefits in ways that others are not. In the absence of consensus on principles, a fair process allows us to agree on what is legitimate and fair. Key elements of fair process will involve transparency about the grounds for decisions; appeals to rationales that all can accept as relevant to meeting health needs fairly; and procedures for revising decisions in light of challenges to them.8 Together these elements assure “accountability for reasonableness.”9 Fair procedures must also be empirically feasible. They must involve practices that can be sustained and that connect well with the goals of various stakeholders in the many institutional settings where these decisions are made. The value of the study by Singer et al in this issue is that it points to key elements of actual decision making processes that can be further improved to achieve legitimacy and fairness (p 1316).1 An ethical approach to fair process must build on their findings. A fair process requires publicity about the reasons and rationales that play a part in decisions. There must be no secrets where justice is involved, for people should not be expected to accept decisions that affect their well being unless they are aware of the grounds for those decisions. The study found that transparency was important to participants in the decisions, though it did not state whether the rationales for decisions were then made transparent to all affected by them. This broader transparency is a hallmark of fair process. Fair process also involves constraints on reasons. Fair minded people—those who seek mutually justifiable grounds for cooperation—must agree that the reasons, evidence, and rationales are relevant to meeting population health needs fairly, the shared goal of deliberation. The kinds of reasons described in the study meet this condition, but the institutions studied—committees concerned with implementing new technologies—did not face the more difficult task of comparing quite different benefits across different groups of patients under budget limits. Fair process also requires opportunities to challenge and revise decisions in light of the kinds of considerations all stakeholders may raise. Though the committees studied by Singer et al gave evidence that decisions improved—that is, became more sensitive to patient variations—through revision, there should be a mechanism for appeals to decisions by those affected by them. The fact that a single lay member of the cardiac committee did not function as effectively as the three lay members of the cancer committee is a lesson that must be taken seriously in designing fair procedures
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The development process of ESMO-MCBS has been compliant with the criteria for 'accountability for reasonableness', which represent the ethical gold-standard for fair priority setting in public policy.
“The development process has been compliant with the criteria for 'accountability for reasonableness' which represent the ethical gold-standard for a fair priority setting process in public policy [134,135].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449 · see citing works
Tudor Hart, J. (1971) · The Lancet · doi:10.1016/s0140-6736(71)92410-x · Cited by 3,253 · see citing works
Daniels, N., & Sabin, J. E. (1997) · Philosophy & Public Affairs · doi:10.1111/j.1088-4963.1997.tb00082.x · Cited by 671 · see citing works
Self-citationPersistence of Use of Lipid-Lowering Medications
Avorn, J., Monette, J., Lacour, A. S., Bohn, R. L., Monane, M., Mogun, H., & LeLorier, J. (1998) · JAMA · doi:10.1001/jama.279.18.1458 · Cited by 635 · see citing works
Wood, D. A., Backer, G. D., Graham, I., Poole-Wilson, P. A., Pyörälà, K., Shepherd, J., Zanchetti, A., Haman, P., Linhartová, K., Simon, J., et al. (1997) · Ghent University Academic Bibliography (Ghent University) · Cited by 537 · see citing works
The Ethics Of Accountability In Managed Care Reform
Daniels, N., & Sabin, J. E. (1998) · Health Affairs · doi:10.1377/hlthaff.17.5.50 · Cited by 306 · see citing works
Self-citationBowker, T. J., Clayton, T. C., Ingham, J., McLennan, N. R., Hobson, H. L., Pyke, S. D. M., Schofield, B., & Wood, D. A. (1996) · Heart · doi:10.1136/hrt.75.4.334 · Cited by 305 · see citing works
Secondary prevention in coronary heart disease: baseline survey of provision in general practice
Campbell, N. C., Thain, J., Deans, H. G., Ritchie, L. D., & Rawles, J. M. (1998) · BMJ · doi:10.1136/bmj.316.7142.1430 · Cited by 236 · see citing works
The second phase of priority setting
Holm, Sabin, J. E., CHINITZ, D. P., Shalev, C., Galai, N., & Israeli, A. (1998) · PubMed · Cited by 169 · see citing works
Primatesta, P., & Poulter, N. R. (2000) · BMJ · doi:10.1136/bmj.321.7272.1322 · Cited by 161 · see citing works
Might treatment of hypercholesterolaemia increase non-cardiac mortality?
Oliver, M. F. (1991) · The Lancet · doi:10.1016/0140-6736(91)93208-q · Cited by 160 · see citing works
The global challenge of health care rationing
Coulter, A., & Ham, C. (2000) · Cited by 152 · see citing works
Priority setting for new technologies in medicine: qualitative case study
SINGER, P. A., Martin, D. K., Giacomini, M. K., & PURDY, L. M. (2000) · BMJ · doi:10.1136/bmj.321.7272.1316 · Cited by 141 · see citing works
RATIONING FAIRLY: PROGRAMMATIC CONSIDERATIONS
Daniels, N. (1993) · Bioethics · doi:10.1111/j.1467-8519.1993.tb00288.x · Cited by 131 · see citing works
Self-citationTragic Choices in Health Care: The Case of Child B
(1998) · Nursing Management · doi:10.7748/nm.5.3.38.s28 · Cited by 26 · see citing works
NICE: a step forward in the quality of NHS care
Horton, R. (1999) · The Lancet · doi:10.1016/s0140-6736(99)00098-7 · Cited by 18 · see citing works
Neil, H., Fowler, G., Patel, H. K., Eminton, Z. B., & Maton, S. (1999) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1999.tb11767.x · Cited by 11 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [3]Ham C, McIver S. Contested decisions: priority setting in the NHS. London: King's Fund; 2000. [Google Scholar]
- [6]NHS Executive. Faster access to modern treatment: how NICE appraisal will work. Leeds: NHS Executive; 1999. [Google Scholar]
Cited by
Sorted by citations
Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series
Lewin, S., Booth, A., Glenton, C., Munthe-Kaas, H., Rashidian, A., Wainwright, M., Bohren, M. A., Tunçalp, Ö., Colvin, C. J., Garside, R., et al. (2018) · Implementation Science · doi:10.1186/s13012-017-0688-3 · Cited by 1,231 · see citing works
Greenhalgh, T., Hinton, L., Finlay, T., Macfarlane, A., Fahy, N., Clyde, B., & Chant, A. (2019) · Health Expectations · doi:10.1111/hex.12888 · Cited by 1,059 · see citing works
Principles for allocation of scarce medical interventions
Persad, G., Wertheimer, A., & Emanuel, E. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60137-9 · Cited by 929 · see citing works
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818 · see citing works
ESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641 · see citing works
Welch, V. A., Akl, E. A., Guyatt, G., Pottie, K., Eslava-Schmalbach, J., Ansari, M. T., de Beer, H., Briel, M., Dans, T., Dans, I., et al. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.01.014 · Cited by 131 · see citing works
“Ideally (although not always practical because of resources available for the guideline development), guideline panels will explicitly weigh equity considerations using a fair and deliberative process, with opportunity for revisions based on feedback and consultation with relevant stakeholders [22].”
BackgroundDal-Ré, R., Becker, S. L., Bottieau, E., & Holm, S. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00119-0 · Cited by 59 · see citing works
Patient and interest organizations’ views on personalized medicine: a qualitative study
Budin-Ljøsne, I., & Harris, J. R. (2016) · BMC Medical Ethics · doi:10.1186/s12910-016-0111-7 · Cited by 32 · see citing works
- Authors
- Daniels, N.
- Affiliations
- Tufts University (US)
- Corresponding author
- Daniels, N.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2000-11-25
- Volume
- 321
- Issue
- 7272
- Pages
- 1300-1301
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- PMC
- PMC1119050
- OpenAlex
- W2022396606
- Cited by
- 729
- References
- 17
- Citations by year
- 2026: 28 · 2025: 26 · 2024: 30 · 2023: 24 · 2022: 34 · 2021: 56 · 2020: 76 · 2019: 50 · 2018: 39 · 2017: 30 · 2016: 42 · 2015: 29 · 2014: 33 · 2013: 21 · 2012: 34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- BMJ (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics and bioethics in healthcare
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Health Professions › General Health Professions › Health Services Management and Policy
- Keywords
- health technology assessment, priority setting, health care rationing, fair decision-making, accountability for reasonableness, transparency, public legitimacy, mixed health systems, managed care, National Institute for Clinical Excellence, pluralism, resource allocation, patient well-being, reasonable disagreement, appeal to authority
- MeSH terms
- United Kingdom, Health Policy, Health Priorities, Humans, Social Responsibility, State Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review